Document is current
Any future updates will be listed below
-
Authors
Biswas, Subir
Mandal, Gunjan
Payne, Kyle K.
Anadon, Carmen M. https://orcid.org/0000-0002-8851-4545
Gatenbee, Chandler D. https://orcid.org/0000-0002-9730-5964
Chaurio, Ricardo A.
Costich, Tara Lee
Moran, Carlos
Harro, Carly M.
Rigolizzo, Kristen E. https://orcid.org/0000-0003-0222-0683
Mine, Jessica A.
Trillo-Tinoco, Jimena
Sasamoto, Naoko https://orcid.org/0000-0002-4526-2181
Terry, Kathryn L.
Marchion, Douglas
Buras, Andrea
Wenham, Robert M.
Yu, Xiaoqing
Townsend, Mary K.
Tworoger, Shelley S.
Rodriguez, Paulo C. https://orcid.org/0000-0001-7480-6566
Anderson, Alexander R. https://orcid.org/0000-0002-2536-4383
Conejo-Garcia, Jose R. https://orcid.org/0000-0001-6431-4074
- License Information
-
More Information
Article History
Received: 22 September 2019
Accepted: 17 December 2020
First Online: 3 February 2021
Competing interests
: J.R.C.-G. has stock options and sponsored research, and receives consulting fees from Compass Therapeutics and Anixa Biosciences. He also receives consulting fees from Leidos. R.M.W. reports grants and personal fees from Merck, personal fees from Tesaro/GSK, personal fees from Genentech, personal fees from Legend Biotech, personal fees from AbbVie, personal fees from AstraZeneca, grants and stock from Ovation Diagnostics, personal fees from Clovis Oncology and personal fees from Regeneron, outside the submitted work. Otherwise, the authors do not have any conflicts of interest.
